Style | Citing Format |
---|---|
MLA | Pakzad B, et al.. "Strong Association of Polymorphism in Spred2 Gene With Disease Susceptibility and Clinical Characteristics of Rheumatoid Arthritis in the Iranian Population." Avicenna Journal of Medical Biotechnology, vol. 14, no. 2, 2022, pp. 170-174. |
APA | Pakzad B, Moghadammanesh H, Salesi M, Salehi R (2022). Strong Association of Polymorphism in Spred2 Gene With Disease Susceptibility and Clinical Characteristics of Rheumatoid Arthritis in the Iranian Population. Avicenna Journal of Medical Biotechnology, 14(2), 170-174. |
Chicago | Pakzad B, Moghadammanesh H, Salesi M, Salehi R. "Strong Association of Polymorphism in Spred2 Gene With Disease Susceptibility and Clinical Characteristics of Rheumatoid Arthritis in the Iranian Population." Avicenna Journal of Medical Biotechnology 14, no. 2 (2022): 170-174. |
Harvard | Pakzad B et al. (2022) 'Strong Association of Polymorphism in Spred2 Gene With Disease Susceptibility and Clinical Characteristics of Rheumatoid Arthritis in the Iranian Population', Avicenna Journal of Medical Biotechnology, 14(2), pp. 170-174. |
Vancouver | Pakzad B, Moghadammanesh H, Salesi M, Salehi R. Strong Association of Polymorphism in Spred2 Gene With Disease Susceptibility and Clinical Characteristics of Rheumatoid Arthritis in the Iranian Population. Avicenna Journal of Medical Biotechnology. 2022;14(2):170-174. |
BibTex | @article{ author = {Pakzad B and Moghadammanesh H and Salesi M and Salehi R}, title = {Strong Association of Polymorphism in Spred2 Gene With Disease Susceptibility and Clinical Characteristics of Rheumatoid Arthritis in the Iranian Population}, journal = {Avicenna Journal of Medical Biotechnology}, volume = {14}, number = {2}, pages = {170-174}, year = {2022} } |
RIS | TY - JOUR AU - Pakzad B AU - Moghadammanesh H AU - Salesi M AU - Salehi R TI - Strong Association of Polymorphism in Spred2 Gene With Disease Susceptibility and Clinical Characteristics of Rheumatoid Arthritis in the Iranian Population JO - Avicenna Journal of Medical Biotechnology VL - 14 IS - 2 SP - 170 EP - 174 PY - 2022 ER - |